Last updated: February 22, 2026
What is the drug associated with NDC 76385-0126?
NDC 76385-0126 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved for spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. It is a one-time infusion designed to deliver a functional copy of the survival motor neuron 1 (SMN1) gene.
Market Overview
Market Size and Conduct
The SMA gene therapy market comprises a handful of authorized products, Limiting competition to primarily Zolgensma and Novartis' Spinraza (nusinersen). Zolgensma gained rapid adoption due to its single-dose regimen and transformative approach.
- Global SMA market size (2022): Estimated at $2.6 billion, expected to grow annually 7-9% through 2027.
- U.S. market share (2022): Approximately 60-70%, driven by early adoption in high-income regions.
- Patient Population:
- Children under 2 years old in market estimates roughly 300-350 new cases annually in the U.S.
- Globally, approximately 600-700 new cases are identified annually.
Competitive Landscape
| Drug |
Approval Year |
Administration |
Cost (per dose) |
Indicated Age |
Market Share (2022) |
| Zolgensma (76385-0126) |
2019 |
Single IV dose |
~$2.1 million |
Under 2 years |
60-70% |
| Spinraza |
2016 |
Intrathecal (multiple doses) |
~$750,000/year |
All ages |
30-40% |
Key Market Drivers
- Regulatory Approvals: Expanded indications and reimbursement policies enhance market penetration.
- Pricing and Reimbursement: Recent prices are scrutinized; payer negotiations impact net revenue.
- Pipeline Developments: Emerging gene therapies and SMN modulators may influence future growth and competition.
Price Projections
Current Pricing and Revenue
- List Price: ~$2.1 million for a one-time infusion.
- Reimbursement Rates: Varies by country; in the U.S., insurance coverage is generally favorable for approved gene therapies.
- Pricing Trends: Slight reductions occur via negotiations, especially with value-based arrangements.
Future Price Trends
| Year |
Projected List Price |
Rationale |
| 2023 |
$2.1 million |
Maintains current premium positioning |
| 2024 |
$2.0 million |
Slight discounting due to competition, negotiations |
| 2025 |
$1.9 million |
Market saturation, regional pricing pressures |
| 2026 |
$1.8 million |
Emergence of biosimilars or alternative therapies |
Revenue Projections (U.S. Market)
| Year |
Estimated Annual Patients |
Total Revenue (USD billions) |
Notes |
| 2023 |
200 |
0.42 |
Stable adoption |
| 2025 |
230 |
0.44 |
Growing diagnosis awareness |
| 2027 |
250 |
0.45 |
Market maturation |
Assumptions Underpinning Price and Revenue Forecasts:
- Stable approval status and no major safety concerns.
- Continued reimbursement support from payers.
- No significant entry of lower-priced or more efficacious competitors.
Risks Affecting Market and Pricing
- Regulatory Challenges: Delays or restrictions on reimbursement can impede revenue.
- Market Penetration: Limited by awareness, diagnosis rates, and patient eligibility.
- Manufacturing Constraints: Capitation and supply chain issues could limit access and price stability.
- Pricing Policies: Governments increasingly scrutinize high-cost therapies.
Key Takeaways
- NDC 76385-0126 (Zolgensma) is a leading gene therapy option for SMA with approximately $2.1 million list price.
- The U.S. market accounts for roughly 60-70% of sales, with global demand expanding.
- Revenue projections indicate stable growth, with pricing slightly declining over time due to market pressures.
- Competition remains limited but could emerge from biosimilar or novel therapies.
- Market growth relies heavily on diagnosis rates, reimbursement policies, and manufacturing capacity.
FAQs
1. How does Zolgensma's pricing compare to Spinraza?
Zolgensma's single-dose price (~$2.1 million) exceeds Spinraza's annual cost (~$750,000/year), but the therapy's efficacy and convenience often justify premiums.
2. What factors could lower Zolgensma's price?
Market competition, negotiated discounts, biosimilar entries, and policy pressures on high-cost drugs could reduce net prices.
3. Are there emerging competitors?
Current pipeline candidates could threaten Zolgensma's market share but none are yet approved.
4. How does the approval for different age groups influence sales?
Expanded indications to older patients could significantly increase sales volume, although current use remains primarily in infants under 2 years.
5. What are the reimbursement outlooks?
Payer acceptance remains favorable in many markets, supported by cost-effectiveness assessments, but regional and institutional differences persist.
References
- [1] Molnar, G. G., & Finkel, R. S. (2022). Gene therapies for spinal muscular atrophy: Market landscape and pricing. Journal of Neuromuscular Diseases, 9(2), 123-132.
- [2] IQVIA. (2022). Global Pharmaceutical Market Trends. IQVIA Institute.
- [3] U.S. FDA. (2019). Zolgensma approval announcement.
- [4] NICE. (2021). Appraisal of Zolgensma for SMA.
- [5] Market Data Forecast. (2023). SMA gene therapies market analysis.
